Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Scientech Research LLC

Scientech Research LLC grew its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 271.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,307 shares of the company's stock after purchasing an additional 22,152 shares during the period. Scientech Research LLC's holdings in Henry Schein were worth $1,943,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Summit Securities Group LLC acquired a new stake in shares of Henry Schein during the 2nd quarter worth about $31,000. Beach Investment Counsel Inc. PA acquired a new stake in shares of Henry Schein in the second quarter worth approximately $37,000. Blue Trust Inc. boosted its position in shares of Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company's stock worth $60,000 after acquiring an additional 475 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of Henry Schein in the first quarter worth approximately $97,000. Finally, Palisade Asset Management LLC acquired a new stake in shares of Henry Schein in the first quarter worth approximately $113,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of HSIC opened at $70.86 on Friday. Henry Schein, Inc. has a 1 year low of $60.01 and a 1 year high of $82.63. The company has a market cap of $9.07 billion, a price-to-earnings ratio of 23.94, a price-to-earnings-growth ratio of 2.01 and a beta of 0.86. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. The firm has a fifty day moving average of $70.04 and a 200-day moving average of $70.26.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. The business had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.31 earnings per share. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares of the company's stock, valued at $4,978,026.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.14% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on HSIC. Baird R W raised shares of Henry Schein from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 22nd. Barrington Research reiterated an "outperform" rating and set a $82.00 price objective on shares of Henry Schein in a research note on Friday, September 20th. JPMorgan Chase & Co. dropped their price target on shares of Henry Schein from $88.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, August 12th. Robert W. Baird dropped their price target on shares of Henry Schein from $92.00 to $82.00 and set an "outperform" rating for the company in a research note on Wednesday, August 7th. Finally, UBS Group dropped their price target on shares of Henry Schein from $75.00 to $72.00 and set a "neutral" rating for the company in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $77.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.